Share: Facebook Twitter LinkedIn
Activity Provided By:


Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma

Access Activity

Overview / Abstract:

As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administration of bispecific antibodies for R/R MM. The content emphasizes the crucial role of the team in improving the timing and quality of treatment as well as facilitating equitable access. This education tailors learning to your needs, providing an ongoing reference tool to enhance care in this complex landscape.


Mar 18, 2025


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video, Workbook

Credits / Hours

1.0 hours



Presenters / Authors / Faculty

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland Clinic
Cleveland, OH

Rebecca LaRue, PharmD, BCOP
Clinical Pharmacy Specialist Hematology/Oncology/Cellular Therapy
Team Lead Hematology/Oncology Pharmacy
Rush University Medical Center
Chicago, IL

Surbhi Sidana, MD
Assistant Professor of Medicine
Director, Myeloma Cellular Immunotherapy & Myeloma Disease Focused Group
Division of BMT & Cell Therapy
Stanford University
Stanford, CA

Sponsors / Supporters / Grant Providers

This educational activity is presented in collaboration with Rush University Medical Center and Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Pfizer, Inc.

Keywords / Search Terms

ACHL Digital practice guide, cancer care, relapsed, refractory, multiple myeloma, RRMM, treatment-related toxicity, comorbidities, multidisciplinary oncology team, bispecific antibodies, bispecific antibodies for R/R MM, biomarkers, oncology, comorbidities, sequencing therapies, disease progression, hematologic malignancy, refractory (R/R) disease, BCMA, GPRC5D, elranatamab, teclistamab, talquetamab Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map